Formulary Chapter 13: Skin - Full Chapter
|
Notes: |
Dermatology services are provided by visiting consultants from Salford Royal Foundation Trust, and choice of therapy is therefore guided by SRFT's formulary. To confirm the formulary status of a product, please see http://www.srft.nhs.uk/for-professionals/formulary/ |
|
Details... |
13.04 |
Topical corticosteroids |
|
|
Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 3% (Diprosalic®) (Potency: Potent)
|
Formulary
|
Ointment
Scalp Application
|
|
Betamethasone (as Valerate) 0.025% (Betnovate-RD®) (Potency: Moderate)
|
Formulary
|
Cream
Ointment
|
|
Betamethasone (as Valerate) 0.1% (Betnovate Scalp®) (Potency: Potent)
|
Formulary
|
Scalp application
|
|
Betamethasone (as Valerate) 0.1% (Non-proprietary or Betnovate®) (Potency: Potent)
|
Formulary
|
Cream
Ointment
|
|
Betamethasone Valerate 0.1% Scalp Application (Betacap®) (Potency: Potent)
|
Formulary
|
Scalp application
|
|
Clobetasol Propionate 0.05% (Dermovate®) (Potency: Very Potent)
|
Formulary
|
Cream
Ointment
Scalp Application
|
|
Clobetasol Propionate 0.05% (Etrivex®) (Potency: Very Potent)
|
Restricted
|
Shampoo
Dermatology only
|
|
Clobetasone Butyrate 0.05% (Eumovate®) (Potency: Moderate)
|
Formulary
|
Cream
Ointment
|
|
Fludroxycortide (Haelan®) (Potency: Moderate)
|
Formulary
|
Cream
Ointment
Tape (for chronic localised recalcitrant dermatoses, but not acute or weeping)
|
|
Fluocinolone Acetonide 0.0025% (Synalar 1 in 10 Dilution®) (Potency: Mild)
|
Formulary
|
Cream
|
|
Fluocinolone Acetonide 0.00625% (Synalar 1 in 4 Dilution®) (Potency: Moderate)
|
Formulary
|
Cream
Ointment
|
|
Fluocinolone Acetonide 0.025% (Synalar®) (Potency: Potent)
|
Formulary
|
Cream
Gel
Ointment
|
|
Fluocinonide 0.05% (Metosyn®)
|
Restricted
|
FAPG cream
Dermatology only
|
|
Hydrocortisone (Potency: Mild)
|
Formulary
|
Cream (0.5%, 1%, 2.5%)
Ointment (0.5%, 1%, 2.5%)
|
|
Hydrocortisone 1%, Urea 10% and Lactic Acid 5% (Calmurid HC®) (Potency: Moderate)
|
Formulary
|
Cream
|
|
Hydrocortisone Butyrate 0.1% (Locoid®) (Potency: Potent)
|
Formulary
|
Cream
Ointment
|
|
Mometasone Furoate 0.1% (Non-proprietary or Elocon®) (Potency: Potent)
|
Restricted
|
Cream
Ointment
Dermatology only
|
|
|
|
13.04 |
With antimicrobials |
|
|
Betamethasone (as Valerate) 0.1% with Clioquinol (Non proprietary or Betnovate-C®) (Potency: Potent)
|
Formulary
|
Cream
Ointment
|
|
Betamethasone (as Valerate) 0.1% with Fucidic Acid 2% (Fucibet®) (Potency: Potent)
|
Formulary
|
Cream
|
|
Betamethasone (as Valerate) 0.1% with Neomycin Sulphate 0.5% (Non-proprietary or Betnovate-N®) (Potency: Potent)
|
Formulary
|
Cream
Ointment
|
|
Betamethasone Dipropionate 0.064% with Clotrimazole 1% (Lotriderm®) (Potency: Potent)
|
Formulary
|
Cream
|
|
Clobetasone butyrate 0.05% with Oxytetracycline and Nystatin (Trimovate®) (Potency: Moderate)
|
Formulary
|
Cream
|
|
Fluocinolone Acetonide 0.025% with Clioquinol 3% (Synalar C®) (Potency: Potent)
|
Formulary
|
Cream
Ointment
|
|
Fluocinolone Acetonide 0.025% with Neomycin Sulphate 0.5% (Synalar N®) (Potency: Potent)
|
Formulary
|
Cream
Ointment
|
|
Hydrocortisone 0.5% with Nystatin and Chlorhexidine (Nystaform-HC®) (Potency: Mild)
|
Formulary
|
Cream
Ointment
|
|
Hydrocortisone 0.5% with Nystatin, Benzalkonium and Dimeticone (Timodine®) (Potency: Mild)
|
Formulary
|
Cream
|
|
Hydrocortisone 1% with Clotrimazole 1% (Canesten HC®) (Potency: Mild)
|
Formulary
|
Cream
|
|
Hydrocortisone 1% with Miconazole Nitrate 2% (Daktacort®) (Potency: Mild)
|
Formulary
|
Cream
Ointment
|
MHRA Safety Alert: serious interactions between topical miconazole and warfarin
|
Hydrocortisone Acetate 1% with Fusidic Acid 2% (Fucidin H®) (Potency: Mild)
|
Formulary
|
Cream
|
|
Triamcinolone Acetonide 0.1% with Chlortetracycline Hydrochloride 3% (Aureocort®) (Potency: Potent)
|
Formulary
|
Ointment
|
|
.... |
Non Formulary Items |
Alclometasone Dipopionate (Modrasone®)

|
Non Formulary
|
|
|
Beclometasone Dipropionate 0.025%

|
Non Formulary
|
|
|
Betamethasone (as Dipropionate) 0.05% (Diprosone®)

|
Non Formulary
|
|
|
Betamethasone Esters (Betesil®)

|
Non Formulary
|
|
|
Betamethasone valerate 0.12% (Bettamousse®)

|
Non Formulary
|
|
|
Clobetasol propionate (Clarelux®)

|
Non Formulary
|
|
|
Clobetasol Propionate with Neomycin and Nystatin

|
Non Formulary
|
|
|
Diflucortolone Valerate (Nerisone Forte®)

|
Non Formulary
|
|
|
Diflucortolone Valerate 0.1% (Nerisone®)

|
Non Formulary
|
|
|
Doxepin Hydrochloride (Xepin®)

|
Non Formulary
|
|
|
Fluocortolone (Ultralanum Plain®)

|
Non Formulary
|
|
|
Fluticasone Propionate (Cutivate®)

|
Non Formulary
|
|
|
Hydrocortisone (Dioderm®) (0.1%)

|
Non Formulary
|
|
|
Hydrocortisone (Efcortelan®)

|
Non Formulary
|
|
|
Hydrocortisone (Hydromol® HC Intensive)

|
Non Formulary
|
|
|
Hydrocortisone (Mildison®)

|
Non Formulary
|
|
|
Hydrocortisone 0.25% Crotamiton 10% (Eurax-Hydrocortisone®)

|
Non Formulary
|
DISCONTINUED |
|
Hydrocortisone 1% with Urea 10% (Alphaderm®)

|
Non Formulary
|
|
|
Hydrocortisone 1%, Clioquinol 3% (Vioform-Hydrocortisone®)

|
Non Formulary
|
|
|
Hydrocortisone Acetate 1% with Oxytetracycline 3% (Terra-Cortril®)

|
Non Formulary
|
|
|
Hydrocortisone Butyrate (Locoid Crelo®)

|
Non Formulary
|
|
|
Hydrocortisone Butyrate 0.1% with Chlorquinaldol 3% (Locoid C®)

|
Non Formulary
|
DISCONTINUED |
|
Hydrocortisone with antimicrobials (Econacort®)

|
Non Formulary
|
|
|
Tri-Adcortyl®

|
Non Formulary
|
|
|
|
Key |
|
|
Cytotoxic Drug
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
Status |
Description |

|
Drugs designated amber are suitable for shared care arrangements under a shared care protocol.
Prescribing may be transferred from secondary to primary care once the patient is stabilised and agreed shared care arrangements have been established. Alternatively primary care may initiate under the supervision of secondary care if this option is given in the shared care document. It is recommended that shared care arrangements should be drawn up following local discussion and agreement by prescribing parties.
|

|
These products have been reviewed by the GM Joint Formulary Group and have been deemed not suitable for prescribing for adults in primary or secondary care within Greater Manchester. These decisions have been made on the basis of safety, efficacy and cost-effectiveness of the products. |

|
Not used
|

|
Drugs designated green1 are suitable for initiation and ongoing prescribing within primary care. |

|
Drugs designated green2 can be initiated by primary care following written or verbal advice from a specialist and then be subsequently safely prescribed in primary care with little or no monitoring required. |

|
Drugs designated green3 are suitable for on-going prescribing within primary care after specialist initiation and an initial review (unless specified) in secondary care. Little or no monitoring is required. |

|
Not suitable for routine prescribing but may be suitable for a defined patient population. Whilst prescribers should think very carefully before prescribing or recommending any of the products on the grey list, there may be exceptional instances when the use of one of these products is necessary for a particular patient. |

|
Drugs designated red are considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy, this may include arranging for supply via a home care company.
|
|
|
|